Eurofarma Innovation and Growth Strategy

23 23 Key Consolidated Financial Indicators 1H22 Results (R$ million)1 Net Revenue 1- Variation compared to 1H21 2- Adjusted for R&D expenses R&D R$ 3,852 Adjusted EBITDA² Gross Profit Operating Expenses eurofarma +13% R$ 2,567 +14% R$ 1,591 +5% Gross Margin -1.0 p.p. 66% % Net Revenue 41% -2.8 p.p. Net Income $ R$ 210 % Net Revenue 5.5% +35% +0.9 p.p. R$ 1,178 Adjusted EBITDA Margin 31% +28% +3.6 p.p. R$ 483 Net Margin 13% +11% -0.1 p.p. Operating Cash Flow R$ 1,166 +199

View entire presentation